Posted by Michael Wonder on 12 Feb 2024
RadioMedix and Orano Med receive FDA breakthrough therapy designation for AlphaMedix in gastro-enteropancreatic neuroendocrine tumours
12 February 2024 - First targeted alfa therapy to receive a breakthrough therapy designation.
RadioMedix and Orano Med today announced that the US FDA has granted breakthrough therapy designation to AlphaMedix (212Pb-dotamtate) for the treatment of adult patients with unresectable or metastatic, progressive somatostatin receptor expressing gastro-enteropancreatic neuroendocrine tumours who are naïve to peptide receptor radionuclide therapy.
